Verified July 2026 · Cited to primary sources
Tirzepatide: Evidence Grade A. FDA-approved / proven in humans.
The honest verdict
Grade A, and on raw efficacy it is the strongest weight-loss drug approved to date, beating semaglutide head to head. If you are choosing between the two, that is a clinical and access conversation, not a science one. We grade the molecule here and hand off the shopping. For provider comparison and where to get tirzepatide, go to glp1picks.com, our sister site built for exactly that.
Tirzepatide at a glance
- Class
- GIP and GLP-1 dual receptor agonist
- Mechanism
- A single peptide that activates two incretin receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The dual agonism appears to produce greater appetite suppression and metabolic effect than GLP-1 alone, which is the leading explanation for its edge over semaglutide on weight and HbA1c.
- Also known as
- Zepbound, Mounjaro, LY3298176
- Research applications
- Chronic weight management
- Type 2 diabetes glycemic control
- Obstructive sleep apnea in obesity
- Forms
- Subcutaneous injection (weekly pen or vial)
- Legal status
- FDA-approved
- WADA (anti-doping)
- Not on the WADA Prohibited List (2025). Not classified as performance-enhancing.
- Evidence grade
- Grade AFDA-approved / proven in humans
How we grade evidence
Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is Tirzepatide?
The dual-hormone agonist that beat semaglutide head to head and delivered up to roughly 21 percent body-weight loss in its pivotal obesity trial, the most weight loss of any approved medication to date.
A single peptide that activates two incretin receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The dual agonism appears to produce greater appetite suppression and metabolic effect than GLP-1 alone, which is the leading explanation for its edge over semaglutide on weight and HbA1c.
How strong is the evidence for Tirzepatide?
FDA-approved for chronic weight management and type 2 diabetes, supported by the SURMOUNT and SURPASS phase 3 programs. SURMOUNT-1 showed mean body-weight reductions of 15.0, 19.5, and 20.9 percent across the 5, 10, and 15 mg doses at 72 weeks versus 3.1 percent on placebo. SURPASS-2 showed it was superior to semaglutide 1 mg on both HbA1c and weight. Unambiguous grade A.
Primary sources (2)
Is Tirzepatide legal? (Status July 2026)
Prescription via a licensed provider.
What is Tirzepatide used for?
Tirzepatide is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.
What does Tirzepatide cost, and how do you access it legally?
Typical cost
Varies widely by source and coverage
Brand and compounded pricing move with supply and coverage. We do not quote provider prices here. For current provider pricing and access, see our sister site glp1picks.com.
How to access it legally
Tirzepatideis FDA-approved, so the legal route is a prescription from a licensed provider, not a research vial. We don't currently have a vetted partner to link for it, so there's no button here. Ask a licensed clinician about the branded product. We never point you to gray-market or compounded off-label sources.
Trying to lose weight?
For weight loss, an approved GLP-1 beats this peptide.
No research peptide here has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the options that actually work.
Is Tirzepatidesafe? Side effects & risks
Safety profile mirrors the GLP-1 class and is well-characterized. Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) dominate and are dose-escalation dependent. Carries the same boxed warning for thyroid C-cell tumors (contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2). Watch for pancreatitis, gallbladder disease, and dehydration-related kidney effects. Avoid in pregnancy; it may reduce oral contraceptive absorption around dose changes.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
Tirzepatide FAQ
Is tirzepatide really better than semaglutide?
For weight and blood sugar, the head-to-head SURPASS-2 trial showed tirzepatide was superior to semaglutide 1 mg, and SURMOUNT-1 produced the highest average weight loss of any approved drug (up to about 21 percent). Whether it is the right choice for you also depends on tolerability, access, and cost.
Where do I get tirzepatide and what will it cost?
We do not run provider pricing on this page. Our sister site does exactly that: for a live comparison of providers, prescription routes, and current cost, see glp1picks.com.
Why does tirzepatide cause so much nausea at first?
The GI effects come from slowed gastric emptying and central appetite signaling, and they peak during dose escalation. Most people find they ease over weeks as the dose is titrated up slowly. Persistent vomiting or severe abdominal pain warrants a call to your prescriber.
From our portfolio
Tracking Tirzepatide?
Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.
Keep reading
MOTS-c
An "exercise-mimetic" metabolic peptide. Real mechanistic interest, but human evidence is association-only.
Grade ATesamorelin
One of only two FDA-approved peptides in this space. Proven to cut visceral fat, but approved for a narrow HIV indication.
Grade BRetatrutide
The next-generation weight-loss peptide with the strongest efficacy signal. But it is investigational and not yet available by any legal route.
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.